Oppenheimer downgraded ResMed from Outperform to Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/19/2025 | $280.00 | Overweight | Morgan Stanley |
| 3/19/2025 | Overweight | Morgan Stanley | |
| 1/16/2025 | Buy | Goldman | |
| 1/10/2025 | $252.00 | Neutral | Piper Sandler |
| 12/13/2024 | $250.00 | Hold | Stifel |
| 9/24/2024 | $280.00 | Outperform | Robert W. Baird |
| 9/18/2024 | $180.00 | Peer Perform → Underperform | Wolfe Research |
| 9/4/2024 | Buy → Hold | Needham |